MicroRNA‑424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation

Liming Wu, Feibiao Yang, Bingyi Lin, Xinhua Chen, Shengyong Yin, Feng Zhang, Haiyang Xie, Lin Zhou, Shusen Zheng

Oncology Letters · 2018 · 20 citations · 17 references

DOIFull text

Open access

Concepts

Abstract

MicroRNA-424 (miR-424) has previously been described as a biomarker of poor prognosis in patients with hepatocellular carcinoma (HCC). In the present study, the clinical significance of miR-424 expression in predicting the rate of tumor recurrence in patients with HCC following liver transplantation (LT) was evaluated. miR-424 expression in HCC samples from 121 patients undergoing LT was examined, and the associations between clinical parameters and patient tumor recurrence were evaluated. The miR-424 expression level in cancer tissues was low compared with that in adjacent noncancerous tissues. Multivariate analyses revealed that low miR-424 expression was an independent prognostic factor for tumor recurrence in patients with HCC following liver transplantation. Patients who no longer met the Milan criteria and had decreased miR-424 expression levels exhibited earlier tumor recurrence following LT. In addition, the upregulation of miR-424 expression significantly reduced the migration, invasion and proliferation of HCC cells. Similarly, the downregulation of miR-424 in HCC cells significantly promoted the migration, invasion and proliferation of HCC cells.

References

17